Abstract：
:The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and prostate-specific antigen (PSA) declines in the TAX327 clinical trial, an international phase III randomized trial of one of the two schedules of docetaxel and prednisone compared with mitoxantrone and prednisone. In this study of 1006 men with CRPC, the median serum testosterone level was 14.5 ng per 100 ml (range 0-270), the median BMI was 27 kg m(-2) (range 15.7-46.5), and 26% of men were obese or morbidly obese (BMI>or=30). Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity. In multivariate analysis, neither BMI, presence of obesity, nor baseline testosterone was significantly associated with OS or PSA declines. Higher testosterone levels among obese men suggest incomplete gonadal suppression with current therapies, but these differences may not be clinically relevant in men with CRPC. There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger Mdoi
10.1038/pcan.2008.36subject
Has Abstractpub_date
2009-01-01 00:00:00pages
88-93issue
1eissn
1365-7852issn
1476-5608pii
pcan200836journal_volume
12pub_type
杂志文章abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-018-0041-1
更新日期：2018-09-01 00:00:00
abstract：BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2016.56
更新日期：2017-06-01 00:00:00
abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500471
更新日期：2000-12-01 00:00:00
abstract：BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2012.41
更新日期：2013-03-01 00:00:00
abstract：OBJECTIVE:To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. METHODS:Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. RESULTS:In all, 188 (48%) questionnaires were returned. In t...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500816
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.29
更新日期：2016-12-01 00:00:00
abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500552
更新日期：2002-01-01 00:00:00
abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.33
更新日期：2014-12-01 00:00:00
abstract：:The purpose of this paper is to examine effects of finasteride 5 mg across different age groups in an ethnically diverse population of men with symptomatic benign prostatic hyperplasia (BPH) seen in community urology and primary care practices. Data were combined from two previous placebo-controlled randomised trials ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500202
更新日期：1997-09-01 00:00:00
abstract：:Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimen...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500575
更新日期：2002-01-01 00:00:00
abstract：:The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500765
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Increasing evidence indicates an association between statins and reduced prostate cancer-specific mortality (PCSM). However, significant bias may exist in these studies. One particularly challenging bias to assess is the healthy user effect, which may be quantified by screening patterns. We aimed to evaluate...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-020-0207-5
更新日期：2020-09-01 00:00:00
abstract：BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2011.67
更新日期：2012-06-01 00:00:00
abstract：OBJECTIVE:To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor. METHODS:This is a companion study to a prospective randomized trial, N...
journal_title：Prostate cancer and prostatic diseases
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.pcan.4500792
更新日期：2005-01-01 00:00:00
abstract：:Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500607
更新日期：2002-01-01 00:00:00
abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500963
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-018-0096-z
更新日期：2019-03-01 00:00:00
abstract：:It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2010.16
更新日期：2011-03-01 00:00:00
abstract：BACKGROUND:Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS:In this analysis, we...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-017-0009-6
更新日期：2018-09-01 00:00:00
abstract：:We measured the histologic stromal and epithelial tissue components of the benign (normal) and malignant tissue compartments of Japanese-Americans (J-A) and native Japanese (NJ) men living in Japan. The patient cohort included 25 NJ men undergoing radical prostatectomy (RP) in Nagoya, Japan and 25 J-A (second or third...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500738
更新日期：2004-01-01 00:00:00
abstract：:The Insulin-like Growth Factor (IGF) network in prostate tissue represents a key element in normal and tumour growth. It can provide us with new markers for prognosis or diagnosis and targets for treatment of prostate diseases. This short review introduces the IGF network in general and in the prostate gland, summaris...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500295
更新日期：1999-03-01 00:00:00
abstract：BACKGROUND:Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the progno...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.55
更新日期：2017-03-01 00:00:00
abstract：BACKGROUND:The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS:This study consisted of 11 541 men with co...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2012.54
更新日期：2013-06-01 00:00:00
abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500889
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.4
更新日期：2014-06-01 00:00:00
abstract：:Dose-escalated conformal radiotherapy is increasingly being used to radically treat prostate cancer with encouraging results and minimal long-term toxicity, yet little is known regarding the response of normal or malignant prostate cells to ionizing radiation (IR). To clarify the basis for cell killing during prostate...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500628
更新日期：2003-01-01 00:00:00
abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500839
更新日期：2006-01-01 00:00:00
abstract：:The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined wi...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2011.14
更新日期：2011-09-01 00:00:00
abstract：BACKGROUND:Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and in...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-018-0085-2
更新日期：2019-09-01 00:00:00
abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,meta分析,评审
doi：10.1038/pcan.2014.17
更新日期：2014-09-01 00:00:00
